PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health and supported by a $30 million grant from GAVI Alliance.

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health and supported by the GAVI Alliance.

Team & Approach

PneumoADIP Team:

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health and supported by a $30 million grant from GAVI Alliance.

Orin Levine.

Orin Levine
Executive Director
olevine@jhsph.edu

Before coming to Johns Hopkins as an Associate Professor in the Department of International Health, Dr. Levine spent 5 years at the CDC followed by 3 years with the US National Institutes of Health. Dr. Levine has authored/coauthored more than 50 original research papers and book chapters, including more than 25 on the subject of meningitis and pneumonia and their prevention by vaccination.

Maria Deloria-Knoll.

Maria Deloria-Knoll
Director, Vaccine Research
mknoll@jhsph.edu

Dr. Knoll has over 15 years' experience in the design, conduct, and analysis of clinical trials and epidemiologic studies. She spent 13 years at the National Institute of Allergy and Infectious Diseases at the NIH and, most recently, 3 years at the Feinberg School of Medicine at Northwestern University. Her clinical trials experience includes close working relationships with many large and mid-sized vaccine manufacturers.

Kate O'Brien.

Kate O'Brien
Deputy Director, Vaccine Research
klobrien@jhsph.edu

For the past 5 years Dr. O'Brien has been a faculty member and the Associate Director of Infectious Disease Studies for the Center for American Indian Health at the Johns Hopkins Bloomberg School of Public Health. Her research has focused on vaccine preventable diseases of childhood, with a particular emphasis on S. pneumoniae. Dr. O'Brien is a consultant to WHO on pneumococcal conjugate vaccine trials.


Angeline Nanni.

Angeline Nanni
Director, Vaccine Supply and Finance
ananni@jhsph.edu

Before joining PneumoADIP, Ms. Nanni worked for Baxter Healthcare Corporation as a Senior Manager in the Vaccines Commercial Division, where she was responsible for the strategic planning and market research for new pipeline products. Prior to working in industry, Ms. Nanni worked at Johns Hopkins Bloomberg School of Public Health in Departments of Epidemiology and Mental Health for 7 years.

Hans Kvist.

Hans Kvist
Director, Communications
hkvist@jhsph.edu

Before joining PneumoADIP, Mr. Kvist worked as Global Communication Manager for Novartis in Switzerland. Mr. Kvist came to the PneumoADIP team with more than 20 years of experience from the pharmaceutical industry. For the past 15 years Mr. Kvist has worked with communications on a global level where his work has included scientific symposia program development, publication planning, and public relations.

Thomas Cherian

Thomas Cherian
WHO Liaison to ADIP Team
cheriant@who.int

Dr. Thomas Cherian is a scientist in the Initiative for Vaccine Research at WHO, coordinating a team responsible for research on vaccines against respiratory and vectorborne pathogens. Previously, Dr. Cherian was a Professor of Paediatrics at the Christian Medical College in Vellore, India. He is also a Senior Associate in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, Baltimore. He has authored/coauthored more than 90 scientific articles and book chapters.

Farzana Muhib.

Farzana Muhib
Research Project Coordinator
443.287.2365
fmuhib@jhsph.edu

Ms. Muhib manages all the data and research for the PneumoADIP team. Previously, Ms. Muhib worked at the CDC, where she was a survey coordinator for a national HIV/AIDS Behavioral Research project. She also developed a technical assistance manual for state and local health departments to conduct rapid assessments of HIV/AIDS risk behaviors.

Rabia Akram
Research Project Manager
443.287.8311
rakram@jhsph.edu

Ms. Akram is the Research Project Manager for PneumoADIP. She aids in data and research management. She has a background in psychology, health policy, and community-based programs. Previously, she worked at the American Medical Association and Mount Sinai in Chicago, where she managed the childhood immunization program.

Jennifer Moisi
Surveillance Officer
jmoisi@jhsph.edu

Ms. Moisi is the Surveillance Officer for PneumoADIP. She is currently pursuing a Ph.D in International Health, Disease Prevention and Control at Johns Hopkins Bloomberg School of Public Health where she received a master’s degree in biostatistics. Prior to her appointment as a Surveillance Officer, she worked as a Research Assistant for pneumoADIP in the U.S., in Kenya, and in Mali. She helped to assess and improve surveillance networks and data collection techniques.

Michelle Moncrieffe-Foreman.

Michelle Moncrieffe-Foreman
Communications Manager
410.502.2631
mmoncrie@jhsph.edu

Ms. Moncrieffe-Foreman is the Communications Manager for PneumoADIP. She has a background in journalism, health communications and community-based programs. Most recently, Ms. Moncrieffe-Foreman worked as a consultant for the American Lung Association of Minnesota. Prior to that, she spent ten years working as a journalist and communications consultant in the United States, Tanzania, and the United Kingdom.

Benedicta Kim
Communications Manager
443.287.2364
hekim@jhsph.edu

Ms. Kim is the Communications Manager for PneumoADIP. She has a background in journalism, research, small business management, and community-based programs. Most recently, Ms. Kim worked as a consultant for the PneumoADIP website. Prior to that she was a research assistant at JHSPH Center for Prevention and Early Intervention.

Establish Value, Deliver Value, Communicate Value.

PneumoADIP Approach

The PneumoADIP is organized around three main areas of activities.

  • Establishing the value of vaccination by demonstrating the burden of meningitis and pneumonia caused by pneumococcal bacteria and demonstrate the value of preventing it through vaccination.
  • Communicating effectively to key decision makers the knowledge about disease burden and the value of vaccination by assuring that research data are communicated through appropriate and effective communication channels.
  • Delivering the value of the vaccine by assuring that there is a predictable supply of quality vaccine at an affordable price, an adequate system to deliver it to the children who need it, and the financing to sustain its use.